Drug Trial Radar · NCT03332771
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Last checked: Nov 20, 2026Latest source record: May 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
954
Actual
Start
Dec 1, 2017
Primary completion
Aug 6, 2019
Study completion Sep 6, 2019
Sponsor
- Lead sponsor
- Lexicon PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Nov 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To demonstrate the non-inferiority of Sotagliflozin 400 milligrams (mg) compared to Glimepiride on hemoglobin A1c (HbA1c) reduction at Week 52 in participants with Type 2 Diabetes (T2D) who have inadequate glycemic control with metformin. Secondary Objectives: To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in body weight, systolic blood pressure (SBP) in participants with baseline SBP ≥130 millimeter of mercury (mmHg), SBP in all participants, and proportion of participants with at least 1 documented symptomatic hypoglycemic event (≤70 milligrams per deciliter \[mg/dL\]). * To demonstrate the superiority of Sotagliflozin 400 mg compared to placebo on change in HbA1c, body weight, SBP in participants with baseline SBP ≥130 mmHg, SBP in all participants. * To demonstrate the superiority of Sotagliflozin 200 mg compared to placebo on change in HbA1c. * To demonstrate the non-inferiority of Sotagliflozin 400 mg compared to Glimepiride on change in HbA1c. * To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in HbA1c. * To evaluate the safety and tolerability of Sotagliflozin compared to Glimepiride and placebo.
Conditions
- Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954)Drug
Pharmaceutical form: tablet Route of administration: oral
GlimepirideDrug
Pharmaceutical form: capsule Route of administration: oral
MetforminDrug
Pharmaceutical form: tablet Route of administration: oral
PlaceboDrug
Pharmaceutical form: tablet Route of administration: oral
PlaceboDrug
Pharmaceutical form: capsule Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin A1c at Week 52Time frame: Baseline, Week 52
Locations
142 sites in 4 countries. Site status is shown where the registry gives one.
Investigational Site Number 8407040
Birmingham, Alabama
Investigational Site Number 8407048
Birmingham, Alabama
Investigational Site Number 8407035
Little Rock, Arkansas
Investigational Site Number 8407051
Anaheim, California
Investigational Site Number 8407065
Canoga Park, California
Investigational Site Number 8407078
Carmichael, California
Investigational Site Number 8407089
Downey, California
Investigational Site Number 8407011
Gold River, California
Investigational Site Number 8407044
Greenbrae, California
Investigational Site Number 8407006
Huntington Park, California
Investigational Site Number 8407037
Lemon Grove, California
Investigational Site Number 8407100
Lomita, California
Investigational Site Number 8407033
Long Beach, California
Investigational Site Number 8407019
Los Angeles, California
Investigational Site Number 8407098
Northridge, California
Investigational Site Number 8407094
Norwalk, California
Investigational Site Number 8407106
Pomona, California
Investigational Site Number 8407096
Rancho Cucamonga, California
Investigational Site Number 8407036
Sacramento, California
Investigational Site Number 8407084
Tarzana, California
Investigational Site Number 8407034
Upland, California
Investigational Site Number 8407032
Van Nuys, California
Investigational Site Number 8407004
Walnut Creek, California
Investigational Site Number 8407117
Wildomar, California
Investigational Site Number 8407045
Colorado Springs, Colorado
Investigational Site Number 8407074
Bradenton, Florida
Investigational Site Number 8407027
Clearwater, Florida
Investigational Site Number 8407103
Cooper City, Florida
Investigational Site Number 8407021
Coral Gables, Florida
Investigational Site Number 8407062
Lake Worth, Florida
Investigational Site Number 8407121
Ocoee, Florida
Investigational Site Number 8407024
Orlando, Florida
Investigational Site Number 8407038
Palmetto Bay, Florida
Investigational Site Number 8407093
Pembroke Pines, Florida
Investigational Site Number 8407107
Spring Hill, Florida
Investigational Site Number 8407091
Tampa, Florida
Investigational Site Number 8407113
Tampa, Florida
Investigational Site Number 8407092
West Palm Beach, Florida
Investigational Site Number 8407115
Winter Haven, Florida
Investigational Site Number 8407017
Chicago, Illinois
Showing 40 of 142 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.